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Background: There is great impetus to achieve elimination of mother-to-child transmission of HIV (eMTCT) by 2015,
and part of this is to identify factors to target to achieve the goal. This study thus identified key patient factors for MTCT
in a high HIV prevalence setting in Johannesburg, South Africa. Between November 2010 and May 2012, we conducted
a case–control study among HIV-infected women with HIV-infected (cases) and uninfected (controls) infants diagnosed
around six weeks of age as part of routine, early infant diagnosis. Mothers and infants were identified through registers
in six healthcare facilities that provide antenatal, postpartum and HIV care. Structured interviews were conducted with a
focus on history of HIV infection, antenatal, intrapartum and immediate postpartum management of the mother-infant
pair. Patient-related risk factors for MTCT were identified.
Results: A total of 77 women with HIV-infected infants and 154 with –uninfected infants were interviewed. Among
HIV-infected cases, 13.0% of the women knew their HIV status prior to conception, and 83.1% reported their pregnancies
as unplanned. Antenatal antiretroviral coverage was high in the control group – only 1/154 (0.7%) reported receiving no
prophylaxis or treatment compared with 17/74 (22.9%) of cases. In multivariate analysis, key patient-related risks for HIV
transmission were: unknown HIV status prior to conception (adjusted odds ratio [AOR] = 6.6; 95% CI = 2.4 – 18.4;
p < 0.001); accessing antenatal care after 20 weeks gestation (AOR = 4.3; 95% CI = 2.0 – 9.3; p < 0.001); less than 12 years
of formal education (AOR = 3.4; 95% CI = 1.6 – 7.5; p = 0.002); and unplanned pregnancy (AOR = 2.7; 95% CI = 1.2 to 6.3;
p = 0.022). Mean age at first HIV test was 6.6 weeks (SD = 3.5) for infants who were diagnosed as HIV-infected, and the
mean age at antiretroviral treatment initiation was 10.8 weeks (SD = 4.4). HIV-uninfected infants were diagnosed at a
mean age of 6.0 weeks (SD = 0.2).
Conclusions: Undiagnosed maternal HIV infection prior to conception, unplanned pregnancies, delays in accessing
antenatal care, and low levels of education were the most significant patient risk factors associated with MTCT. While
the emphasis has been on increasing availability and coverage of efficacious antiretroviral regimens, and strengthening
health systems within eMTCT initiatives, there is a need to also address patient-related factors if we are to achieve
eMTCT goals.
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In 2009, UNAIDS, the Joint United Nations Programme
on HIV/AIDS, made a global call for the elimination of
mother-to-child transmission of HIV (eMTCT) by 2015,
and there is great impetus to achieve the target as the
deadline approaches [1-3]. Coupled with this was a call* Correspondence: Coceka.Mnyani@wits.ac.za
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unless otherwise stated.for a 50% reduction in HIV-related maternal mortality
[1]. Elimination is defined as a 90% reduction in the
number of new paediatric HIV infections, or a MTCT
rate below 5% [1]. Great strides have been made in the
field of prevention of mother-to-child transmission
(PMTCT), both globally and in South Africa [3]. Rates
of HIV transmission to children have decreased substan-
tially – among the 21 Global Plan priority countries in
sub-Saharan Africa, including South Africa, MTCT rates
have decreased by around a half or more since 2009 [3].
This decrease is largely attributable to the availability of
efficacious antiretroviral regimens at high coverage [3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mnyani et al. Globalization and Health 2014, 10:36 Page 2 of 7
http://www.globalizationandhealth.com/content/10/1/36However, success of PMTCT initiatives depends on more
than the availability of antiretrovirals. The World Health
Organization’s (WHO’s) comprehensive strategic ap-
proach for PMTCT also includes primary prevention of
HIV infection; prevention of unintended pregnancies in
HIV-infected women; and a family-centred approach to
HIV care [4]. There is also a need to integrate PMTCT
into routine maternal, neonatal, child and women’s
health services [5]. Several studies have demonstrated the
benefits of integration of services, in both the delivery and
utilisation of services [5].
Patient and health system factors are critical in deter-
mining success of PMTCT programmes and attainment
of eMTCT goals [6-9]. While there are effective biomed-
ical interventions for HIV and pregnancy prevention,
patients need timely access to care and then to utilise
the interventions appropriately. Women who are already
pregnant need to access healthcare early and if identified
as HIV-infected, be initiated on antiretrovirals timeously
and also adhere to therapy during the ante- and postpar-
tum periods. While it is well-recognised that the highest
risk of MTCT is among women with undiagnosed and/or
untreated HIV infection, and also in known HIV-infected
women who either do not start or delay treatment, there
are still health system factors that fail to address these
[10-13]. Also, antenatal and HIV services remain largely
segregated, and there is still failure to prioritise pregnant
women for initiation of antiretroviral therapy (ART)
[12,13]. Pregnant women may not access antenatal care
early; may decline ART; or fail to adhere to antiretroviral
regimens. This study thus focused on, and identified key
patient-centred risks for MTCT in a high HIV prevalence
setting in Johannesburg, South Africa.
Methods
Study design
Between November 2010 and May 2011, consecutive
mothers with HIV-infected infants who were referred to
a paediatric HIV clinic for ART initiation were enrolled
(cases). Mothers of uninfected infants (controls), identi-
fied through clinic registers, were recruited at five pri-
mary care facilities between December 2011 and May
2012. Mothers of both HIV-infected and –uninfected in-
fants were all HIV-infected. The decision to obtain con-
trols was taken after analysis of data on mothers of
infected infants showed interesting patterns on patients’
health-seeking behaviour and care accessed during preg-
nancy. The controls and cases were similar with respect
to site of antenatal care, place and date of delivery, and
where infant HIV testing was done. Both group of in-
fants were also born in the same period, but controls
were recruited slightly later than cases.
Twice as many controls as cases were enrolled and a
convenience sample was selected. The initial plan was toenrol more controls, but due to difficulties with recruit-
ment of mothers with uninfected infants and concerns
about recall bias from the lengthy period between the
cases and controls, the ratio was decreased to 2:1. Of the
controls that were contacted, a quarter of them could be
reached and were available to be interviewed. There
were several reasons why mothers of uninfected infants
were unavailable for interview, and these included the
women having returned to work and unable to take time
off; migration; and contact number unavailable or changed.
The 2:1 ratio was deemed adequate for detecting differ-
ences between the two groups.
Participants were interviewed using a structured ques-
tionnaire and data on the following parameters were
collected from the interviews: history of HIV infection –
whether preconception HIV testing was done, and whether
ART was initiated in those identified as HIV-infected; base-
line CD4 cell count; knowledge of partner’s HIV status;
whether the pregnancy was planned; previous exposure to
PMTCT interventions; antenatal and intrapartum prophy-
laxis; infant prophylaxis and feeding option; and timing of
early infant diagnosis. Additional data were collected on
management of infant HIV infection in cases of HIV-
infected infants. Infants diagnosed as either HIV-infected
or –uninfected, through early infant diagnosis, were identi-
fied through facility registers. Interviewers were fluent in
the local vernacular languages used in the interviews. In-
ternal audit processes were conducted on the study data,
including validation of information collected from inter-
views against facility records.
Study setting
Within routine care, all facilities in Soweto, Johannesburg
where the women accessed care provided PMTCT services
during the antenatal and postnatal periods. HIV testing
was routinely offered to all pregnant women, and if
HIV-infected, either antiretroviral prophylaxis or life-
long treatment was initiated, depending on a woman’s
CD4 cell count. All antenatal clinics provided anti-
retroviral prophylaxis, while ART initiation for those
eligible occurred only at selected sites over the study
period. Postnatal testing was offered if a woman’s HIV
status was unknown, and also in those who tested HIV
negative during pregnancy and did not have a repeat test
antenatally. A free six months’ supply of infant formula
was given to HIV-infected women who elected to for-
mula feed. All health facilities offered routine early infant
diagnosis around six weeks of age, but management of
infected infants occurred only at one paediatric HIV
clinic at the time of the study.
Over the study period, uptake of HIV testing within
the antenatal clinics was 99%, and the HIV preva-
lence in pregnant women was around 25% (unpublished
programme data). MTCT risk around six week was 2.7% in
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PMTCT guideline changes (Table 1); most notable was the
initiation of zidovudine prophylaxis from an earlier gesta-
tional age and an increase in CD4 cell count threshold for
ART initiation, from 200 to 350 cells/mm3. There was also
a transition from zidovudine to nevirapine syrup for infant
prophylaxis.
Data analysis
Data were analysed with Stata® version 12.0 (Stata
Corporation, College Station, USA). Continuous data
were summarized using means and medians as appropri-
ate. Standard statistical methods were utilised to assess
differences between children with and without HIV infec-
tion. Descriptive analyses included variable description
and cross tabulation, and inferential analyses included
tests of association by chi-square test. Multivariate logis-
tic regression analysis was done to identify factors associ-
ated with risk of MTCT and results presented as adjusted
odds ratios (AOR) with 95% confidence intervals (CI).
Potential confounding factors associated with the out-
come and exposure (p < 0.10) were included in the initial
multivariate logistic regression models using backward-
fitting. Variables with p < 0.05 were used in the final
model, and those that did not markedly alter the model
fit were removed.
Ethics approval
The study was approved by the University of the
Witwatersrand’s Human Research Ethics Committee,
and also by the Gauteng Provincial Department of
Health. Written informed consent was obtained from study
participants.
Results
Demographics and antenatal parameters
In total, 77 women with HIV-infected infants (cases),
and 154 mothers with HIV-uninfected infants (controls)
were interviewed. Mean age for the cases was 28.1 years
(standard deviation (SD) = 6.4), and for the controlsTable 1 Summary of key changes in South African PMTCT gu
Date PMTCT guidelines
2002 to February 2008 Only intrapartum and infant sdN
2004 ART became available; CD4 thres
February 2008 Maternal AZT (from 28 weeks ge
depending on duration of mater
April 2010 Gestational age for AZT initiation
350 cells/mm3, Infant NVP syrup p
initiation of maternal ART; extende
April 2012 Withdrawal of free infant formula
April 2013 EFV-based FDCs for prophylaxis a
sdNVP single-dose nevirapine; AZT zidovudine; EFV efavirenz; FDCs fixed-dose com30.9 years (SD = 5.5), p = 0.001; (Table 2). The propor-
tion of participants with under 12 years of formal
education was 68.8% for the cases and 44.8% for the
controls, p <0.001. Median parity and gravidity were
two for both groups. Among women with HIV-infected
infants, 83.1% (64/77) had unplanned pregnancies, com-
pared with 56.5% (87/154) of women with uninfected in-
fants, p < 0.001. Median gestational age at first antenatal
visit was 16.0 weeks (interquartile range (IQR) =12 – 20)
for controls, and 24.0 weeks (IQR = 16 – 26) for cases,
p < 0.001. The proportion of women who did not access
any antenatal care was 1.9% (3/154) for controls and
14.3% (11/77) for cases. Of the women who did not ac-
cess antenatal care and had an HIV-infected infant, six
knew that they were HIV-infected. Most reasons for not
accessing antenatal care revolved around fear of stigma-
tisation by either health workers or family.
History of HIV infection
Of women with uninfected infants, 43.5% (67/154) knew
that they were HIV-infected prior to the index pregnancy
compared to 13.0% (10/77) of women with infected infants,
p < 0.001. Slightly more than half of the women with HIV-
uninfected infants knew their partner’s HIV status (56.5%;
87/154), and of the known, three-quarters were HIV-
infected (73.6%), while in the group with infected infants,
37/77 (48.1%) knew their partner’s HIV status, and 94.6%
were HIV-infected. Median baseline CD4 cell count was
315 cells/mm3 (IQR: 203 – 420) for the cases (n = 58), and
355 cells/mm3 (IQR: 210 – 480) for the controls (n = 111).
Of women with HIV-infected infants, 22.9% (17/74) re-
ceived no antenatal antiretroviral prophylaxis or treatment,
while in the group with uninfected infants only one re-
ported no antenatal antiretrovirals. In the cases, 11.7%
(9/77) of the women received antenatal ART, while
42.9% (66/154) received ART in the control group.
Intrapartum and postpartum management
A proportion of women in both groups reported receiv-
ing no intrapartum antiretrovirals – 11 (7.1%) in theidelines
VP available for prophylaxis
hold for ART initiation 200 cells/mm3
station) and infant AZT, for prophylaxis. One to four weeks of infant AZT,
nal prophylaxis or treatment
reduced to 14 weeks, CD4 threshold for ART initiation increased to
rophylaxis introduced for breastfeeding period – six weeks if preconception
d to cover breastfeeding period if no maternal ART
, EFV-based ART regimen approved for pregnant women
nd treatment introduced
binations.
Table 2 Demographics and antenatal parameters of cases
and controls
Characteristics Cases
(n = 77)
Controls
(n = 154)
P-value
Age, mean (SD) 28.1 (6.4) 30.9 (5.5) 0.001
Parity, median (IQR) 2 (1 – 5) 2 (1 – 7) 0.514
Gravidity, median (IQR) 2 (1 – 6) 2 (1 – 7) 0.054
Formal education, n (%)
≤11 years 53 (68.8) 69 (44.8) <0.001
Knew HIV status prior to index pregnancy,
n (%)
10 (13.0) 67 (43.5) <0.001
Knew partner’s HIV status, n (%) 37 (48.1) 87 (56.5) 0.230
Unplanned pregnancy, n (%) 64 (83.1) 87 (56.5) <0.001
Gestational age at 1st antenatal visit,
weeks, n (%)
≤20 weeks 32 (45.5) 115 (78.2) <0.001
*Baseline CD4 count (cells/mm2),
n (%)
≤350 34 (58.6) 54 (48.7) 0.220
Antenatal antiretrovirals received,
n (%)
AZT 48 (62.3) 83 (53.9) <0.001
ART 9 (11.7) 66 (42.9)
None 17 (22.9) 1 (0.7)
Unknown 3 (3.9) 4 (2.6 )
Intrapartum antiretrovirals received,
n (%)
sdNVP 7 (9.1) 35 (22.7) <0.001
sdNVP and AZT 43 (55.8) 15 (9.7)
AZT only 13 (16.9) 36 (23.4)
ART 8 (10.4) 57 (37.0)
None 6 (7.8) 11 (7.1)
*CD4 cell count known for 75.3% of cases (n = 58) 72.1% of controls (n = 111).
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group with infected infants. Fewer women with infected
infants (68/77; 88.3%) than with uninfected infants
elected to formula feed (147/154, 95.4%; p = 0.044). In
the control group, 147/148 (99.3%) infants received
prophylaxis, while 72/76 (94.7%) of the cases did. The
mean infant age at first HIV test was 6.0 weeks (SD =
0.2) for the uninfected infants, and 6.6 weeks (SD = 3.5)
for the infected infants, p = 0.200. At time of interview,
73/77 (94.8%) of the infected infants had already been
initiated on ART, and the mean age at ART initiation
was 10.8 weeks (SD = 4.4; Table 3).
Risk factors for MTCT
In multivariate analysis, unknown HIV status prior to
conception, unplanned pregnancy, accessing antenatal
care after 20 weeks gestation, and less than 12 years offormal education were all identified as important risk
factors for MTCT (Table 4). The odds were 6.6 times
more with an unknown HIV status, while there was a
4.3 fold increase in women presenting for antenatal care
beyond 20 weeks gestation. HIV transmission was 3.4
times more likely among women with less than 12 years
of formal education than those with more education
(AOR 95% CI = 1.6 – 7.5), and with unplanned pregnan-
cies it was 2.7 fold higher (AOR 95% CI = 1.2 – 6.3).
Discussion
This study identified several patient groups at high risk
of MTCT. These were patients with unknown HIV sta-
tus prior to conception; those with unplanned pregnan-
cies; accessing antenatal care after 20 weeks gestation;
and having less than 12 years of formal education.
Slightly more mothers of HIV-infected infants elected to
breastfeed – 11.7% compared to 4.6% of mothers with –
uninfected infants, but this difference was not signifi-
cant. While causality may not be definitively ascertained
from this study, the findings highlight several important
risk factors that must be targeted for eMTCT; availabil-
ity of antiretrovirals alone is not enough.
Of women with HIV-infected infants, only 13.0% knew
that they were HIV-infected prior to conception. The
lowest risk of MTCT is with preconception ART and
the duration of ART is directly related to MTCT risk
[14,15]. HIV-infected women who initiate ART prior to
pregnancy are more likely to be virally suppressed at the
time of delivery – the most important determinant of
MTCT. Even if ART is not initiated prior to pregnancy,
there is an increased likelihood of women with known
HIV status accessing PMTCT care [16]. For those women
who initiate ART during pregnancy, earlier initiation of
treatment is associated with a decreased risk of MTCT,
and each additional week of treatment confers a cumula-
tive reduction in risk [15,17,18].
If we are to eliminate MTCT, there needs to be rou-
tine HIV testing for all women and men of reproductive
age, and ART initiation for those found to be HIV-
infected and eligible for treatment. South Africa imple-
mented large population-based HIV-testing campaigns
in recent years, but it is uncertain if these have impacted
on PMTCT and linkage to care. However, recent unpub-
lished programmatic data from the Soweto PMTCT
programme, where this study was conducted, shows an
increasing proportion of pregnant women presenting
with an already known HIV status, and an increasing
number already on treatment. As HIV testing and treat-
ment programmes expand and become functional, more
women will know their HIV status preconception. They
will however still need to present for antenatal care tim-
eously for early initiation and continuation of appropri-
ate PMTCT interventions. Healthcare services need to
Table 3 Infant delivery and HIV diagnosis details
Variable Cases (n = 77) Controls (n = 154) P-value
Mode of delivery, n (%)
NVD 48 (62.3) 106 (68.8) 0.690
C-section 29 (37.7) 46 (29.9)
Assisted delivery 0 (0.0) 2 (1.3)
¥Birth weight (g), median (IQR) 2850 (2450 – 3100) 2950 (2600 – 3200) 0.122
Infant antiretroviral prophylaxis, n (%)
Prophylaxis received* 72 (94.7) 147 (99.3) 0.030
Infant feeding method, n (%)
Breastfeeding 9 (11.7) 7 (4.6) 0.044
Formula feeding 68 (88.3) 147 (95.4)
Age at 1st HIV test, mean weeks; (SD) 6.6 (3.5) 6.0 (0.2) 0.200
Infant age at HIV-positive diagnosis, mean weeks (SD) 9.0 (4.2) — —
Infant age at ART initiation, mean weeks (SD) 10.8 (4.4) — —
NVD normal vaginal delivery; C-section caesarean section.
*Prophylaxis received: AZT syrup or NVP syrup; n = 76 for cases and n = 148 for controls.
¥Birth weight, n = 158 for controls – 4 sets of twins.
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testing and initiation of ART in those found to be
eligible.
One area that is under-researched, but increasingly
shown to be important in the success of PMTCT inter-
ventions, is male partner involvement [19-21]. Encour-
aging male partners to be involved in antenatal care,
including routine HIV testing for themselves, has been
shown to increase the likelihood of HIV-infected preg-
nant women accessing and adhering to treatment [19,20].
More importantly, it has been linked with a decreased
risk of MTCT, and increased HIV-free survival in HIV-
uninfected infants [21]. In our study, less than half of
the women with infected infants knew their partners’
HIV status, and of the known, the majority were HIV-
infected; the proportions were marginally better for
women with HIV-uninfected infants, but still suboptimal.
There are several barriers to male partner involvement in
PMTCT programmes, and more broadly in sexual and
reproductive health services. Some of the most pertinent
barriers identified include the cultural perception, and
often societal norm, that men do not participate in repro-
ductive health services and that the facilities where theseTable 4 Multivariate analysis of risk factors for MTCT
Factors Adjusted odds ratio
AOR (95% CI)
P-value
Unplanned pregnancy 2.7 (1.2 – 6.3) 0.022
≤ 11 years of formal education 3.4 (1.6 – 7.5) 0.002
First antenatal visit after 20 weeks 4.3 (2.0 – 9.3) <0.001
Unknown HIV status prior to index
pregnancy
6.6 (2.4 – 18.4) <0.001are offered are not male-friendly [22]. Various strategies
have been utilised to encourage more male partner par-
ticipation, and amongst them, healthcare provider-driven
initiatives to invite men to be part of reproductive and
PMTCT programmes, and community-based strategies
which include male peer support groups and community
campaigns [22,23].
Rates of unplanned pregnancies were high, especially
amongst women who had infected infants – 83.1% of
the pregnancies were unplanned. Family planning, and
consequently prevention of unintended pregnancies, has
long been the most underutilised PMTCT intervention,
with only modest progress to date [24]. In addition
to decreased risk of MTCT, planned pregnancies are
also associated with better obstetric outcomes, with de-
creased maternal morbidity and mortality [24]. There
remains a high unmet need for contraception among
HIV-infected women, and even in those who have ac-
cess to reproductive health services, rates of unplanned
pregnancies remain high [25,26]. Integration of repro-
ductive health and PMTCT is one of the suggested
strategies for improving the reproductive health out-
comes of HIV-infected women [27]. There is however a
need for stronger programmatic efforts and implemen-
tation research for integration to work [27].
Timing of antenatal care influences diagnosis and ap-
propriate management of maternal HIV infection. In our
study, accessing antenatal care beyond 20 weeks gesta-
tion was associated with an increased MTCT risk. This
is consistent with findings from other studies where late
presentation for antenatal care delayed initiation of ap-
propriate PMTCT interventions, increasing the risk of
perinatal transmission [16,17]. Lack of integration of
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in HIV-infected women initiating treatment [28]. There
are several reasons why pregnant women either do not
access antenatal care, or delay doing so, and these include
lack of access to care; poor knowledge about timing and
need to present for care; and unavailability of services
[29]. It is also important that once HIV-infected women
access antenatal care, they remain in care. While adher-
ence to ART has been shown to be higher prenatally than
postpartum, there is still significant loss to follow-up in
the PMTCT continuum of care, and patient and health
system factors have been identified as contributing fac-
tors [16]. There is a need for targeted interventions, both
prenatally and postpartum, to ensure that HIV-infected
women remain in care.
While there is increased public knowledge of HIV in-
fection, stigma remains a reality for many, especially
women. In our study, there were women who knew that
they were HIV-infected, but still did not access antenatal
care due to fear of being stigmatised by either health
workers or family. There’s a need to address stigma at all
levels, as it has been shown to impact health-seeking be-
haviour and adherence to treatment [30]. Patient infor-
mation on PMTCT interventions should be simplified
and reinforced at every opportunity; understanding and
adherence to treatment need not depend on level of
education. A low level of formal education was one of
the risk factors for MTCT identified. Inadequate know-
ledge of PMTCT interventions among health workers
was also highlighted in a cross-sectional survey assessing
quality of care within the same Soweto programme as
this study [31].
Despite the challenges identified, the study provides
several reassuring findings. Routine early infant diagnosis,
and ART initiation in those found to be HIV-infected were
timeous. At the time of the study, 94.8% of the HIV-
infected infants had already been initiated on ART, and the
mean age at ART initiation was 10.8 weeks.
While this study makes an important contribution to
our knowledge of the requirements for an effective
PMTCT programme, and highlights the importance of
patient factors as we work towards elimination of MTCT,
there are limitations. Causality cannot be inferred be-
tween the negative patient factors identified and risk of
MTCT. There was also a lag period between the inter-
views of cases and that of controls, and this could have
contributed to recall bias amongst the controls as they
were interviewed at a much later period post-delivery.
The sample of controls might also not have been repre-
sentative as there was a high percentage that could not
be reached, and some of the infants might have died dur-
ing the lag period as it is a recognised fact that despite
being uninfected, the morbidity and mortality rate in
HIV-exposed infants remains significant. We also reliedon self-reported information, but this was found to be re-
liable when compared to hospital records.
Conclusions
Despite the limitations, the study provides important
insights as we work towards eMTCT. As much as avail-
ability and implementation of efficacious PMTCT inter-
ventions are key in preventing HIV infection in children,
individual patient factors are also important and need to
be targeted. Undiagnosed maternal HIV infection prior
to conception, unplanned pregnancies, delays in acces-
sing antenatal care, and low levels of education were
the most significant patient risk factors associated with
MTCT in our study. The focus in resource-constrained
settings has largely been on establishing functioning sys-
tems to facilitate implementation of efficacious PMTCT
interventions, and great strides have been made in this
regard, including in South Africa [24,32]. While contin-
ued strengthening of health systems is crucial, our study
highlights the considerable importance of individual
patient factors for further reducing paediatric HIV infec-
tions. There is a need for further research on why rates
of unplanned pregnancies, and consequently consider-
able delays in accessing antenatal care, remain high.
Also, why the rates of preconception HIV testing remain
low in resource-constrained settings, despite the avail-
ability of interventions to address these factors.
Abbreviations
AIDS: Acquired Immune Deficiency Syndrome; AOR: Adjusted odd ratio;
ART: Antiretroviral therapy; AZT: Zidovudine; CI: Confidence intervals;
C-section: Caesarean section; EFV: Efavirenz; eMTCT: Elimination of mother-to-
child transmission of HIV; FDCs: Fixed dose combinations; HIV: Human
Immunodeficiency Syndrome; IQR: Interquartile range; MTCT: Mother-to-child
transmission of HIV; NVD: Normal vaginal delivery; NVP: Nevirapine;
PMTCT: Prevention of mother-to-child transmission of HIV; SD: Standard
deviation; sdNVP: single-dose nevirapine; UNAIDS: Joint United Nations
Programme on HIV/AIDS; WHO: World Health Organization.
Competing interests
We declare that we have no conflicts of interest.
Authors’ contributions
CNM conceptualised the study and wrote the manuscript. AS performed the
statistical analysis. MC helped to draft the manuscript. JM assisted with the
statistical analysis. JAM participated in the study design and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The Anova Health Institute’s Soweto PMTCT programme is supported by the
US President’s Emergency Plan for AIDS Relief (PEPFAR) via the US Agency
for International Development, under Cooperative Agreement No. 674-A-00-
08-00009-00. The views expressed in this report do not necessarily reflect
those of PEPFAR or USAID.
We thank Helen Struthers for her support in conducting the study, Landon
Myer for assistance with the study design, and Edmore Marinda for assistance
with the data analysis.
Author details
1Department of Obstetrics and Gynaecology, and School of Public Health,
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
South Africa. 2Anova Health Institute, 12 Sherborne Road, Parktown, 2193
Johannesburg, South Africa. 3Centre for Health Policy, School of Public
Mnyani et al. Globalization and Health 2014, 10:36 Page 7 of 7
http://www.globalizationandhealth.com/content/10/1/36Health, University of Witwatersrand, Johannesburg, South Africa. 4Wits
Reproductive Health and HIV Research Institute, Faculty of Health Sciences,
University of the Witwatersrand, Johannesburg, South Africa. 5International
Centre for Reproductive Health, Department of Obstetrics and Gynaecology,
Ghent University, Ghent, Belgium. 6School of Public Health and Family
Medicine, University of Cape Town, Cape Town, South Africa.
Received: 14 November 2013 Accepted: 10 April 2014
Published: 15 May 2014
References
1. WHO, UNICEF, UNFPA, UNAIDS: Towards the elimination of mother-to-child
transmission of HIV: Report of a technical consultation, 9–11 November 2010.
Geneva, Switzerland.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS): Countdown to Zero:
global plan towards the elimination of new HIV infections among children by
2015 and keeping their mothers alive, 2011–2015. Geneva: UNAIDS; 2011.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS): 2013 Progress report
on the global plan: towards the elimination of new HIV infections among children
by 2015 and keeping their mothers alive. Geneva: UNAIDS; 2013.
4. World Health Organization: Strategic approaches to the prevention of HIV
infection in infants: report of a WHO meeting. Morges, Switzerland: WHO;
2003. 20–22 March 2002.
5. Lindegren ML, Kennedy CE, Bain-Brickley D, Azman H, Creanga AA,
Butler LM, Spaulding AB, Horvath T, Kennedy GE: Integration of HIV/
AIDS services with maternal, neonatal and child health, nutrition,
and family planning services. Cochrane Database of Syst Rev 2012,
9:Art. No.: CD010119. doi:10.1002/14651858.CD010119.
6. Mofenson LM: Prevention in neglected subpopulations: prevention of
mother-to-child transmission of HIV infection. Clin Infect Dis 2010,
50(S3):S130–S148.
7. Lyons C, Mushavi A, Ngobeni-Allen F, Yule R, Abrams E: Ending pediatric
AIDS and achieving a generation born HIV-free. J Acquir Immune Defic
Syndr 2012, 60(S2):S35–S38.
8. Barker PM, Mphatswe W, Rollins N: Antiretrovirals in the cupboard are not
enough: the impact of health systems’ performance on mother-to-child
transmission of HIV. J Acquir Immune Defic Syndr 2011, 56:e45–e48.
9. Doherty T, Chopra M, Nsibande D, Mngoma D: Improving the coverage of
the PMTCT programme through a participatory quality improvement
intervention in South Africa. BMC Public Health 2009, 9:406.
10. Myer L: Initiating antiretroviral therapy in pregnancy: the importance of
timing. J Acquir Immune Defic Syndr 2011, 58:125–126.
11. Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, Anderson J,
Hawkins DA, Taylor GP, de Ruiter A, London HIV Perinatal Research Group:
When should HAART be initiated in pregnancy to achieve an
undetectable HIV viral load by delivery? AIDS 2012, 26:1095–1103.
12. Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L: Initiation of highly
active antiretroviral therapy among pregnant women in Cape Town,
South Africa. Trop Med Int Health 2010, 15:825–832.
13. Myer L, Zulliger R, Bekker LG, Abrams E: Systemic delays in the initiation of
antiretroviral therapy during pregnancy do not improve outcomes of
HIV-positive mothers: a cohort study. BMC Pregnancy Childbirth 2012,
12:94.
14. Whitmore SK, Taylor AW, Espinoza L: Correlates of mother-to-child
transmission of HIV in the United States and Puerto Rico. Pediatr
2012, 129:e74–e81.
15. Hoffman R, Black V, Technau K, van der Merwe KJ, Currier J, Coovadia A,
Chersich M: Effects of highly active antiretroviral therapy duration and
regimen on risk of mother-to-child transmission of HIV in Johannesburg,
South Africa. J Acquir Immune Defic Syndr 2010, 54(1):35–41.
16. Technau K, Kalk E, Coovadia A, Black V, Pickerill S, Mellins CA, Abrams EJ,
Strehlau R, Kuhn L: Timing of maternal HIV testing and uptake of
prevention of mother-to-child transmission interventions among women
and their infected infants in Johannesburg, South Africa. J Acquir Immune
Defic Syndr 2014, 65:e170–e178.
17. Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, Chi BH,
Stringer JS, Stringer EM: Optimal time on HAART for prevention of
mother-to-child transmission of HIV. J Acquir Immune Defic Syndr
2011, 58(2):224–228.
18. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA:
Low rates of mother-to-child transmission of HIV following effectivepregnancy interventions in the United Kingdom and Ireland, 2000–2006.
AIDS 2008, 22(8):973–981.
19. Farquhar C, Kiarie JN, Richardson BA, Kabura MN, John FN, Nduati RW,
Mbori-Ngacha DA, John-Stewart GC: Antenatal couple counseling
increases uptake of interventions to prevent HIV-1 transmission.
J Acquir Immune Defic Syndr 2004, 37(5):1620–1626.
20. Msuya SE, Mbizvo EM, Hussain A, Uriyo J, Sam NE, Stray-Pedersen B: Low
male partner participation in antenatal HIV counselling and testing in
northern Tanzania: implications for preventive programs. AIDS Care 2008,
20(6):700–709.
21. Aluisioa A, Richardsonb BA, Bosireg R, John-Stewart G, Mbori-Ngachah D,
Farquharc C: Male antenatal attendance and HIV testing are associated
with decreased infant HIV infection and increased HIV free survival.
J Acquir Immune Defic Syndr 2011, 56(1):76–82.
22. Morfaw F, Mbuagbaw L, Thabane L, Rodrigues C, Wunderlich AP, Nana P,
Kunda J: Male involvement in prevention programs of mother to child
transmission of HIV: a systematic review to identify barriers and
facilitators. Syst Rev 2013, 2:5.
23. Kululanga LI, Sundby J, Malata A, Chirwa E: Striving to promote male
involvement in maternal health care in rural and urban settings in
Malawi - a qualitative study. Reprod Health 2011, 8:36.
24. Joint United Nation Programme on HIV/AIDS (UNAIDS): Report on the global
AIDS epidemic 2013. Geneva: UNAIDS; 2013.
25. Sarnquist CC, Rahangdale L, Maldonado Y: Reproductive health and family
planning needs among HIV-infected women in Sub-Saharan Africa.
Curr HIV Res 2013, 11(2):160–168.
26. Wanyenze RK, Tumwesigye NM, Kindyomunda R, Beyeza-Kashesya J,
Atuyambe L, Kansiime A, Neema S, Ssali F, Akol Z, Mirembe F: Uptake of
family planning methods and unplanned pregnancies among HIV-
infected individuals: a cross-sectional survey among clients at HIV clinics
in Uganda. J Int AIDS Soc 2011, 14:35.
27. Wilcher R, Hoke T, Adamchak SE, Cates W Jr: Integration of family
planning into HIV services: a synthesis of recent evidence. AIDS
2013, 27(Suppl 1):S65–S75.
28. Stinson K, Jennings K, Myer L: Integration of antiretroviral therapy services
into antenatal care increases treatment initiation during pregnancy:
a cohort study. PLoS One 2013, 8(5):e63328.
29. Kisuule I, Kaye DK, Najjuka F, Ssematimba SK, Arinda A, Nakitende G, Otim L:
Timing and reasons for coming late for the first antenatal care visit by
pregnant women at Mulago hospital, Kampala Uganda. BMC Pregnancy
Childbirth 2013, 13(1):121.
30. Rahangdale L, Banandur P, Sreenivas A, Turan JM, Washington R, Cohen CR:
Stigma as experienced by women accessing prevention of parent-to-
child transmission of HIV services in Karnataka, India. AIDS Care 2010,
22(7):836–842.
31. Mnyani CN, McIntyre JA: Challenges to delivering quality care in a prevention
of mother-to-child transmission of HIV programme in Soweto. S Afr J HIV Med
2013, 14(2):64–69.
32. Barron P, Pillay Y, Doherty T, Sherman G, Jackson D, Bhardwaj S, Robinson P,
Goga A: Elimination of mother-to-child HIV transmission in South Africa.
Bull World Health Organ 2013, 91:70–74.
doi:10.1186/1744-8603-10-36
Cite this article as: Mnyani et al.: Patient factors to target for elimination
of mother-to-child transmission of HIV. Globalization and Health
2014 10:36.
